Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

BACKGROUND & AIMS A randomized placebo-controlled trial evaluated the efficacy of natalizumab induction therapy in patients with Crohn's disease. METHODS Patients (N = 509) with moderately to severely active Crohn's disease and active inflammation characterized by elevated C-reactive protein concentrations were randomized (1:1) to receive natalizumab 300… CONTINUE READING